StockCIK 1645460
Cue Biopharma, Inc. (CUE): Insider Trades and Fund Holdings
In the past 12 months, Cue Biopharma, Inc. insiders reported 0 open-market purchases worth $0 and 7 sales worth $2.43M; 0 of the sales were reported as made under a 10b5-1 trading plan.
0Insider buys, 12 months
$0Bought by insiders, 12 months
$2.43MSold by insiders, 12 months
1Tracked funds holding
Recent insider trades
Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Oct 14, 2026.
| Filed | Insider | Type | Value |
|---|---|---|---|
| Oct 14 | Shao-Lee LinCEO | ▼ SELL | $305K |
| Oct 14 | Sumita RayGeneral Counsel | ▼ SELL | $52K |
| Oct 14 | Michael Vincent MeluzioVP | ▼ SELL | $32K |
| Aug 17 | Sumita RayGeneral Counsel | ▼ SELL | $266K |
| Aug 17 | Michael Vincent MeluzioVP | ▼ SELL | $169K |
| Aug 14 | Shao-Lee LinCEO | ▼ SELL | $1.08M |
| Aug 14 | Shao-Lee LinCEO | ▼ SELL | $523K |
Source: SEC Form 4 filings, retrieved Oct 28, 2026. How we read filings
Insiders who traded in the past year
| Insider | Role | Buys | Bought | Sells | Sold |
|---|---|---|---|---|---|
| Shao-Lee Lin | CEO | 0 | $0 | 3 | $1.91M |
| Sumita Ray | General Counsel | 0 | $0 | 2 | $317K |
| Michael Vincent Meluzio | VP | 0 | $0 | 2 | $201K |
ADVERTISEMENT
320 × 100 ad slot
Tracked funds that report CUE
From each fund's latest 13F. Holdings are as of quarter end and are filed up to 45 days later.
| Fund | Shares | Value | Change |
|---|---|---|---|
| Renaissance Technologies | 14,689 | $464K | ▲ New |
Source: SEC Form 13F-HR filings, retrieved Oct 28, 2026. How we read filings
Reading these numbers
Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →